News and Updates

Merck and NMIMS join forces to launch the CATALYST programme, an industry-ready initiative designed to train the next generation of pharmaceutical experts.

OKYO Pharma files its annual report, confirming a stable cash position and detailing strategic plans to advance Phase 3 clinical trials for ocular therapy.

New research confirms that decentralized clinical trials improve patient access and diversity by removing geographic barriers to medical research.

Armata Pharmaceuticals advances AP-SA02 toward Phase 3, hitting key clinical and manufacturing milestones to combat resistant Staphylococcus aureus infections.

Bayer and Henry Ford Health have joined forces to broaden access to clinical trials, aiming to accelerate medical research and improve patient diversity.

New research shows bioavailable CurcuBoost curcumin significantly reduces knee osteoarthritis symptoms. Discover the latest findings on this adjunct therapy.

Bayer and Henry Ford Health have partnered to accelerate clinical trial access, leveraging EHR technology to improve research participation and patient care.

Discover the hidden operational and patient-care challenges at investigative sites when corporate acquisitions trigger the sudden closure of Phase 3 trials.

Explore how the synergy between englumafusp and glofitamab is transforming oncology trial design and setting new benchmarks for bispecific cancer therapy.

Akeso has launched a Phase II trial for AK146D1, a new treatment for advanced NSCLC. Learn about this critical development in lung cancer clinical research.